Can Companies Patent Human Genes?

Monday, April 15, 2013

Today the Supreme Court hears arguments in Association for Molecular Pathology v. Myriad Genetics, Inc., a case that will determine whether companies have the right to patent human genes. 

The case centers on Myriad Genetics, a company that patented the BRCA1 and BRCA2 genes in 1994. For women, the presence of either BRCA gene indicates increased risk of breast and ovarian cancer. Myriad Genetics discovered the genes and developed the test to determine whether patients have them.

Myriad claims that their patent corresponds to the effort their scientists expended to find the genes, rather than the genes themselves. The Association for Medical Pathology and its supporters, on the other hand, argue that the genes themselves are being patented and that, because the genes are naturally occurring, Myriad did not create a new product deserving of a patent.

Tom Taylor, assistant managing editor at Bloomberg BNA and US Law Week, explains the legal issues at hand, along with Harriet Washington, who examines the potential medical and bioethics consequences of this case.


Tom Taylor and Harriet Washington

Produced by:

Jillian Weinberger

Comments [2]

Flynn from Texas

I've lost many family members to the results of BRCA1. If Myriad could take it _out_ of my family's genetic code, they would be welcome to whatever rights to it they desired. 'Til then, their ownership of it is moot - I want my doctor to have any and all access to my genetics, not a third party.

Apr. 15 2013 12:43 PM

Speaking of courts and bioethics,
nothing on the Philadelphia doctor trial?

Apr. 15 2013 10:36 AM

Leave a Comment

Email addresses are required but never displayed.